166 related articles for article (PubMed ID: 31401746)
1. Cost-Effectiveness of Pneumococcal Vaccination and Uptake Improvement Programs in Underserved and General Population Adults Aged < 65 Years.
Wateska AR; Nowalk MP; Lin CJ; Harrison LH; Schaffner W; Zimmerman RK; Smith KJ
J Community Health; 2020 Feb; 45(1):111-120. PubMed ID: 31401746
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of adult pneumococcal vaccination policies in underserved minorities aged 50-64 years compared to the US general population.
Wateska AR; Nowalk MP; Lin CJ; Harrison LH; Schaffner W; Zimmerman RK; Smith KJ
Vaccine; 2019 Mar; 37(14):2026-2033. PubMed ID: 30846259
[TBL] [Abstract][Full Text] [Related]
3. Cost-Effectiveness of Pneumococcal Vaccination Policies and Uptake Programs in US Older Populations.
Wateska AR; Nowalk MP; Lin CJ; Harrison LH; Schaffner W; Zimmerman RK; Smith KJ
J Am Geriatr Soc; 2020 Jun; 68(6):1271-1278. PubMed ID: 32086950
[TBL] [Abstract][Full Text] [Related]
4. Is further research on adult pneumococcal vaccine uptake improvement programs worthwhile? Α value of information analysis.
Wateska AR; Nowalk MP; Jalal H; Lin CJ; Harrison LH; Schaffner W; Zimmerman RK; Smith KJ
Vaccine; 2021 Jun; 39(27):3608-3613. PubMed ID: 34045104
[TBL] [Abstract][Full Text] [Related]
5. Changes in the cost-effectiveness of pneumococcal vaccination and of programs to increase its uptake in U.S. older adults.
Wateska AR; Nowalk MP; Altawalbeh SM; Lin CJ; Harrison LH; Schaffner W; Zimmerman RK; Smith KJ
J Am Geriatr Soc; 2024 Jun; ():. PubMed ID: 38822745
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of an in-development adult-formulated pneumococcal vaccine in older US adults.
Wateska AR; Nowalk MP; Lin CJ; Harrison LH; Schaffner W; Zimmerman RK; Smith KJ
Vaccine; 2023 Jul; 41(30):4431-4437. PubMed ID: 37316409
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of revised US pneumococcal vaccination recommendations in underserved minority adults < 65-years-old.
Wateska AR; Patricia Nowalk M; Lin CJ; Harrison LH; Schaffner W; Zimmerman RK; Smith KJ
Vaccine; 2022 Nov; 40(50):7312-7320. PubMed ID: 36336526
[TBL] [Abstract][Full Text] [Related]
8. Pneumococcal Vaccination Strategies in 50-Year-Olds to Decrease Racial Disparities: A US Societal Perspective Cost-Effectiveness Analysis.
Altawalbeh SM; Wateska AR; Nowalk MP; Lin CJ; Harrison LH; Schaffner W; Zimmerman RK; Smith KJ
Value Health; 2024 Jun; 27(6):721-729. PubMed ID: 38462225
[TBL] [Abstract][Full Text] [Related]
9. Cost-Effectiveness of Newly Recommended Pneumococcal Vaccination Strategies in Older Underserved Minority Adults in the USA.
Smith KJ; Wateska AR; Nowalk MP; Lin CJ; Harrison LH; Schaffner W; Zimmerman RK
Infect Dis Ther; 2022 Aug; 11(4):1683-1693. PubMed ID: 35831685
[TBL] [Abstract][Full Text] [Related]
10. An intervention to improve pneumococcal vaccination uptake in high risk 50-64 year olds vs. expanded age-based recommendations: an exploratory cost-effectiveness analysis.
Wateska AR; Nowalk MP; Lin CJ; Harrison LH; Schaffner W; Zimmerman RK; Smith KJ
Hum Vaccin Immunother; 2019; 15(4):863-872. PubMed ID: 30633706
[TBL] [Abstract][Full Text] [Related]
11. Economic evaluation of standing order programs for pneumococcal vaccination of hospitalized elderly patients.
Middleton DB; Lin CJ; Smith KJ; Zimmerman RK; Nowalk MP; Roberts MS; Fox DE
Infect Control Hosp Epidemiol; 2008 May; 29(5):385-94. PubMed ID: 18521990
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of pneumococcal conjugate vaccination in Croatia.
Vučina VV; Filipović SK; Kožnjak N; Stamenić V; Clark AD; Mounaud B; Blau J; Hoestlandt C; Kaić B
Vaccine; 2015 May; 33 Suppl 1():A209-18. PubMed ID: 25919163
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of pneumococcal and influenza vaccination standing order programs.
Lin CJ; Zimmerman RK; Smith KJ
Am J Manag Care; 2013 Jan; 19(1):e30-7. PubMed ID: 23379777
[TBL] [Abstract][Full Text] [Related]
14. Pneumococcal Vaccination in Adults Aged ≥65 Years: Cost-Effectiveness and Health Impact in U.S. Populations.
Wateska AR; Nowalk MP; Lin CJ; Harrison LH; Schaffner W; Zimmerman RK; Smith KJ
Am J Prev Med; 2020 Apr; 58(4):487-495. PubMed ID: 32001052
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of increasing vaccination in high-risk adults aged 18-64 Years: a model-based decision analysis.
Wateska AR; Nowalk MP; Zimmerman RK; Smith KJ; Lin CJ
BMC Infect Dis; 2018 Jan; 18(1):52. PubMed ID: 29370768
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness of 13-valent pneumococcal conjugate vaccine (PCV13) in older Australians.
Dirmesropian S; Wood JG; MacIntyre CR; Beutels P; McIntyre P; Menzies R; Reyes JF; Chen C; Newall AT
Vaccine; 2017 Aug; 35(34):4307-4314. PubMed ID: 28693751
[TBL] [Abstract][Full Text] [Related]
17. Cost-Effectiveness of the 4 Pillars Practice Transformation Program to Improve Vaccination of Adults Aged 65 and Older.
Smith KJ; Zimmerman RK; Nowalk MP; Lin CJ
J Am Geriatr Soc; 2017 Apr; 65(4):763-768. PubMed ID: 28024090
[TBL] [Abstract][Full Text] [Related]
18. Retrospective cost-effectiveness of the 23-valent pneumococcal polysaccharide vaccination program in Australia.
Chen C; Beutels P; Wood J; Menzies R; MacIntyre CR; McIntyre P; Newall AT
Vaccine; 2018 Oct; 36(42):6307-6313. PubMed ID: 30213457
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of conjugate pneumococcal vaccination in Singapore: comparing estimates for 7-valent, 10-valent, and 13-valent vaccines.
Tyo KR; Rosen MM; Zeng W; Yap M; Pwee KH; Ang LW; Shepard DS
Vaccine; 2011 Sep; 29(38):6686-94. PubMed ID: 21745516
[TBL] [Abstract][Full Text] [Related]
20. Impact and cost effectiveness of pneumococcal conjugate vaccine in India.
Krishnamoorthy Y; Eliyas SK; Nair NP; Sakthivel M; Sarveswaran G; Chinnakali P
Vaccine; 2019 Jan; 37(4):623-630. PubMed ID: 30587430
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
